Subanesthetic intravenous (IV) racemic ketamine, an N-methyl-D-aspartate (NMDA) antagonist, produces rapid and potent antidepressant effects in patients with treatment-resistant depression.

Authors

• Person: Not available Organization: Frontiers in Psychiatry
  The Montreal model: an integrative biomedical-psychedelic ...

Sources

• The Montreal model: an integrative biomedical-psychedelic ... www.frontiersin.org Frontiers in Psychiatry via serper

Referenced by nodes (1)

• treatment-resistant depression concept